Townsend, Claire L; O'Rourke, John; Milanzi, Edith; Collins, Intira Jeannie; Judd, Ali; Castro, Hannah; Vicari, Marissa; ... Penazzato, Martina; + view all Townsend, Claire L; O'Rourke, John; Milanzi, Edith; Collins, Intira Jeannie; Judd, Ali; Castro, Hannah; Vicari, Marissa; Jesson, Julie; Leroy, Valériane; Renaud, Françoise; Penazzato, Martina; - view fewer (2022) Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review. Journal of the International AIDS Society , 25 (11) , Article e25970. 10.1002/jia2.25970.

Preview

PDF Journal of the International AIDS Society - 2022 - Townsend - Effectiveness and safety of dolutegravir and raltegravir for.pdf - Published Version Download (2MB) | Preview

Abstract

INTRODUCTION: Globally about 1.7 million children were living with HIV in 2020. Two integrase strand transfer inhibitors, dolutegravir and raltegravir, are increasingly used in children. We conducted a systematic review to assess the effectiveness and safety of dolutegravir and raltegravir in children and adolescents living with HIV, aged 0–19 years. METHODS: Sources included MEDLINE, Embase, the Cochrane Library, clinical trial registries, abstracts from key conferences and reference list searching. Observational studies and clinical trials published January 2009–March 2021 were eligible. Outcomes included efficacy/effectiveness (CD4 counts and viral load) and/or safety outcomes (mortality, grade 3/4 adverse events and treatment discontinuation) through 6 months or more post-treatment initiation. Risk of bias was assessed using previously published tools appropriate for the study design. Narrative syntheses were conducted. RESULTS AND DISCUSSION: In total, 3626 abstracts and 371 papers were screened. Eleven studies, including 2330 children/adolescents, reported data on dolutegravir: one randomized controlled trial (RCT; low risk of bias), one single-arm trial (unclear risk of bias) and nine cohort studies (three low risk of bias, two unclear risk and four high risk). Ten studies, including 649 children/adolescents receiving raltegravir, were identified: one RCT (low risk of bias), one single-arm trial (low risk of bias) and eight cohort studies (four low risk of bias, three unclear risk and one high risk). Viral suppression levels in children/adolescents at 12 months were high (>70%) in most studies assessing dolutegravir (mostly second- or subsequent-line, or mixed treatment lines), and varied from 42% (5/12) to 83% (44/53) at 12 months in studies assessing raltegravir (mostly second- or subsequent-line). Across all studies assessing dolutegravir or raltegravir, grade 3/4 adverse events (clinical and/or laboratory) were reported in 0–50% of subjects, few resulted in discontinuation, few were drug related and no deaths were attributed to either drug. CONCLUSIONS: These reassuring findings suggest that dolutegravir and raltegravir are effective and safe as preferred regimens in children and adolescents living with HIV. With the rollout of dolutegravir in paediatric populations already underway, it is critical that data are collected on safety and effectiveness in infants, children and adolescents, including on longer-term outcomes, such as weight and metabolic changes.

Downloads since deposit

Loading...

228Downloads

Download activity - last month

Export as CSVJSONXML

Loading...

Download activity - last 12 months

Export as XMLCSVJSON

Loading...

Downloads by country - last 12 months

Export as JSONCSVXML

Loading...

Archive Staff Only

View Item